{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:40:00Z","timestamp":1778845200656,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T00:00:00Z","timestamp":1561593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.vaccine.2019.06.053","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T10:16:33Z","timestamp":1564222593000},"page":"4830-4834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-7248","authenticated-orcid":false,"given":"Bruce L.","family":"Innis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Berlanda","family":"Scorza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy S.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varsha K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastazia Older","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane J.","family":"Post","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niteen","family":"Wairagkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Bresee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.vaccine.2019.06.053_b0005","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2019.06.053_b0010","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1016\/j.vaccine.2019.06.080","article-title":"Meeting report: convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity","volume":"37","author":"Innis","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2019.06.053_b0015","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1172\/JCI101633","article-title":"Protective effect of vaccination against induced influenza A","volume":"24","author":"Francis","year":"1945","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.vaccine.2019.06.053_b0020","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1172\/JCI101634","article-title":"Protective effect of vaccination against induced influenza B","volume":"24","author":"Salk","year":"1945","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.vaccine.2019.06.053_b0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/jmv.1890030303","article-title":"Attenuated influenza produced by experimental intranasal inoculation","volume":"3","author":"Little","year":"1979","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2019.06.053_b0030","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/aje\/kwm375","article-title":"Time lines of infection and disease in human influenza: a review of volunteer challenge studies","volume":"167","author":"Carrat","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2019.06.053_b0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijid.2016.05.013","article-title":"Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies","volume":"49","author":"Balasingam","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.053_b0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fmicb.2016.00080","article-title":"Using the ferret as an animal model for investigating influenza antiviral effectiveness","volume":"7","author":"Oh","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2019.06.053_b0045","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fcimb.2019.00107","article-title":"The future of flu: a review of the human challenge model and systems biology for advancement of influenza vaccinology","volume":"9","author":"Sherman","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2019.06.053_b0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1586\/erv.12.77","article-title":"Clinical, scientific and ethnographic studies of influenza in quarantine","volume":"11","author":"Oxford","year":"2012","journal-title":"Expert Rev Vacc"},{"issue":"5","key":"10.1016\/j.vaccine.2019.06.053_b0055","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2125.1976.tb00640.x","article-title":"Distribution and removal of human serum albumin-technetium 99m instilled intranasally","volume":"3","author":"Aoki","year":"1976","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.06.053_b0060","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3181\/00379727-122-31255","article-title":"Human influenza resulting from aerosol inhalation","volume":"122","author":"Alford","year":"1966","journal-title":"Proc Soc Exp Biol Med"},{"issue":"5","key":"10.1016\/j.vaccine.2019.06.053_b0065","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/infdis\/124.5.473","article-title":"Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man","volume":"124","author":"Couch","year":"1971","journal-title":"J Infect Dis"},{"issue":"Pt 3","key":"10.1016\/j.vaccine.2019.06.053_b0070","first-page":"391","article-title":"The internal surface area of the adult human lung","volume":"112","author":"Hasleton","year":"1972","journal-title":"J Anat"},{"key":"10.1016\/j.vaccine.2019.06.053_b0075","unstructured":"World Health Organization. Measles aerosol vaccine project \u2013 report to Sage; 2012. https:\/\/www.who.int\/immunization\/sage\/meetings\/2012\/november\/3_MeaslesAerosolVaccineProject-report_SAGE.pdf?ua=1 (accessed November 10, 2018)."},{"issue":"13","key":"10.1016\/j.vaccine.2019.06.053_b0080","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2169\/internalmedicine.0316-17","article-title":"The prevalence and findings of subclinical influenza-associated cardiac abnormalities among Japanese patients","volume":"57","author":"Ito","year":"2018","journal-title":"Intern Med."},{"issue":"10","key":"10.1016\/j.vaccine.2019.06.053_b0085","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2019.06.053_b0090","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.053_b0095","article-title":"Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial","author":"Finberg","year":"2018","journal-title":"J Infect Dis"},{"issue":"9979","key":"10.1016\/j.vaccine.2019.06.053_b0100","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.06.053_b0105","doi-asserted-by":"crossref","unstructured":"Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China; 2010.","DOI":"10.1136\/bmj.c4779"},{"issue":"10","key":"10.1016\/j.vaccine.2019.06.053_b0110","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/cix127","article-title":"Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an individual participant data metaanalysis","volume":"64","author":"Venkatesan","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2019.06.053_b0115","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S2213-2600(17)30174-1","article-title":"Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study","volume":"5","author":"Beigel","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.vaccine.2019.06.053_b0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/infdis\/jir701","article-title":"Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study","volume":"205","author":"Killingley","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.06.053_b0125","unstructured":"National Institute for Health Research. Clinical trials toolkit: risk assessment. http:\/\/www.ct-toolkit.ac.uk\/routemap\/risk-assessment\/ [accessed November 18, 2018]."},{"key":"10.1016\/j.vaccine.2019.06.053_b0130","unstructured":"The 8P Screening Tool. https:\/\/www.hospitalmedicine.org\/globalassets\/clinical-topics\/clinical-pdf\/8ps_riskassess-1.pdf [accessed November 14, 2018]."},{"issue":"1","key":"10.1016\/j.vaccine.2019.06.053_b0135","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12879-018-3220-8","article-title":"Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model","volume":"18","author":"Han","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.06.053_b0140","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02284-17","article-title":"Evaluation of preexisting anti-hemagglutinin stalk antibody as a correlate of protection in a healthy volunteer challenge with influenza A\/H1N1pdm virus","volume":"9","author":"Park","year":"2018","journal-title":"MBio"},{"issue":"2","key":"10.1016\/j.vaccine.2019.06.053_b0145","doi-asserted-by":"crossref","first-page":"e00417","DOI":"10.1128\/mBio.00417-16","article-title":"Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A\/H1N1 virus healthy human challenge model","volume":"7","author":"Memoli","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2019.06.053_b0150","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fmicb.2017.00900","article-title":"Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre","volume":"8","author":"Gould","year":"2017","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.06.053_b0155","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJM198307073090103","article-title":"Cytotoxic T-cell immunity to influenza","volume":"309","author":"McMichael","year":"1983","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2019.06.053_b0160","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.vaccine.2019.06.053_b0165","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.vaccine.2019.06.053_b0170","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1128\/CVI.00397-07","article-title":"Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children","volume":"15","author":"Forrest","year":"2008","journal-title":"Clin Vaccine Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19308151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:29Z","timestamp":1759401269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19308151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":34,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0264410X19308151"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.06.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}